34th week of 2010 patent applcation highlights part 35 |
Patent application number | Title | Published |
20100215612 | ODOR-CONTROLLING BODILY FLUID ABSORBER - An odor-controlling bodily fluid absorbent member comprises (a) an absorbent material or substrate; and (b) a halo active aromatic sulfonamide compound of Formula (I): | 2010-08-26 |
20100215613 | PVA Particle for Temporary Embolic Material and Production Process Thereof, and Temporary Embolic Material - A temporary embolic material for blood vessel which can embolize a blood vessel in a living body and is used for the temporary embolization of the blood stream. More specifically, disclosed is an embolus-forming material comprising a specific PVA particle which can be used for the closure of the inner lumen of a blood vessel by the PVA particle to embolize the blood stream, which can ultimately be absorbed in the living body, which can be excreted out of the body and which does not remain in the body. A pearl-like polyvinyl alcohol particle for use as a temporary embolic material, the particle having a saponification degree of 90 mol % or higher and an average particle diameter of 70 to 1000 μm; and a temporary embolic material comprising the particle mixed or dissolved therein. | 2010-08-26 |
20100215614 | Enterostatin as Inhibitor of Angiogenesis - It has been discovered that enterostatin inhibits angiogenesis in an in vitro adipose tissue angiogenesis model. In concentrations from about 10 | 2010-08-26 |
20100215615 | IMMUNOCYTOKINES FOR CANCER TREATMENT IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS - This invention relates to the treatment of cancer using anti-cancer agents, such as doxorubicin or paclitaxel, in combination with antibody-interleukin 2 (IL2) conjugates which target tenascin-C. | 2010-08-26 |
20100215616 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2010-08-26 |
20100215617 | ENHANCED MEDICAL IMPLANT - A medical implant comprising in components from a tooth and stem cells harvested from at least one tooth. Tooth stem cells may be harvested from the dental pulp of mammalian teeth, such as unerupted third molars in humans. After the stem cells are removed and isolated from the other teeth tissue, the hard tooth may be ground into a base material for the manufacture of a porous matrix into which the tooth stem cells can be added. Additionally, soft tissue from the harvested tooth may be used as a carrier scaffold for soft tissue applications such as meniscal or cartilage repair. | 2010-08-26 |
20100215618 | NOVEL COMPOUNDS - 644 - The invention provides compounds of formula (I) | 2010-08-26 |
20100215619 | HLA PEPTIDE THERAPY - The invention provides polypeptides derived from a major histocompatibility complex (MHC) class I human leukocyte antigen (HLA), such as HLA-A2, and derivatives or analogues thereof. The polypeptides, derivatives and analogues can be used to treat or prevent allosensitisation, such as the treatment or prevention of allograft rejection. | 2010-08-26 |
20100215620 | THE CO-CULTURE METHOD OF SPHINGOMONAS SP. BACTERIAL STRAIN AND ASPERGILLUS SP. FUNGUS STRAIN, NEW ANTI-CANCER AND ANTIBIOTIC GLIONITRINS DERIVED FROM THIS CO-CULTURE METHOD, AND PHARMACEUTICAL COMPOSITION CONTAINING GLIONITRINS OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS AN ACTIVE INGREDIENT - The present invention relates to a co-culture method of | 2010-08-26 |
20100215621 | Recombinant Adenoviruses Capable Of Regulating Angiogenesis - The present invention relates to a recombinant adenovirus capable of regulating angiogenesis, which comprises (a) an adenoviral ITR (inverted terminal repeat) nucleotide sequence; and (b) a transcription regulatory sequence for a VEGF-A (vascular endothelial growth factor-A) gene comprising (i) a nucleotide sequence encoding a DNA binding domain comprising a zinc finger domain to bind to a site in a VEGF-A promoter sequence as set forth in nucleotides 1-2362 of SEQ ID NO:1, and (ii) a transcription activation domain or a transcription inhibitory domain linked to the nucleotide sequence encoding the DNA binding domain; and a pharmaceutical composition comprising the recombinant adenovirus. | 2010-08-26 |
20100215622 | TREATMENT OF IMMUNOSUPPRESSION-RELATED DISORDERS - Disclosed are methods of using blastomere-like stem cells to treat a number of immunodeficiency disorders. | 2010-08-26 |
20100215623 | BONE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS IN BIOCOMPATIBLE MATRIX, AND TREATMENTS THEREOF - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone) when combined with a biocompatible matrix, preferably SIS. The invention further provides methods of using compositions comprising muscle-derived progenitor cells with a biocompatible matrix for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age. | 2010-08-26 |
20100215624 | Pharmaceutical Compositions for Treating Rheumatoid Arthritis Comprising Semi-Mature Dendritic Cell - The present invention relates to a pharmaceutical composition for treating rheumatoid arthritis, which comprises (a) a pharmaceutically effective amount of a semi-mature dendritic cell; and (b) a pharmaceutically acceptable carrier. The semi-mature dendritic cell of this invention has a safe and remarkably improved potential to treat or prevent rheumatoid arthritis through the activity of the suppression of auto-immune responses. | 2010-08-26 |
20100215625 | EFFICIENT PREPARATION OF NAPHTHOQUINONE ANTICANCER ACTIVE INGREDIENTS - One of the problems to be resolved by the present invention is to stably and sustainably produce active ingredients contained in Bignoniaceous plants of which a mass production is difficult in a conventional manner. The present invention relates to a method for efficiently preparing an anticancer active ingredient NQ | 2010-08-26 |
20100215626 | MRSA Decolonization Kit (MDK) - The MRSA Decolonization Kit, or MDK, is a unique process available in a single kit to eliminate MRSA from individuals who have recently suffered an invasive infection from the potentially deadly bacteria and strengthen their body's ability to prevent recurrent infection. The kit provides patients with everything they need to remove MRSA from their skin flora and replace it with a far less dangerous bacteria, | 2010-08-26 |
20100215627 | ATOPY CURE BABY DRY MILK WITH GREEN TEA AND LACTOBACILLUS - Provided is a prevention and treatment of baby atopy using green tea and | 2010-08-26 |
20100215628 | METHOD FOR PREPARING CELL POPULATIONS WITH ANTI-TUMOR IMMUNE RESPONSE ACTIVITY - The invention provides a method for preparing cell populations with anti-tumor immune response activity, which includes co-culturing tumor and mononuclear cell in a three-dimensional cell culture device, separating and amplifying the cell populations with anti-tumor immune response activity from the cultures. The present invention, at the same time, discloses the cell populations with anti-tumor immune response activity obtained by the method and the kit comprising the cell populations. | 2010-08-26 |
20100215629 | TREATMENT OF TUMORS USING T LYMPHOCYTE PREPARATIONS - The invention relates to the treatment of a tumor in a patient, by injecting T lymphocytes depleted of regulatory T lymphocytes, and expressing a molecule allowing their specific destruction, the patient receiving beforehand a non-myeloablative or myeloablative lymphopenic treatment. | 2010-08-26 |
20100215630 | Plant-derived Protectants Against Ultraviolet Light - The present invention relates to plant extracts and formulations and kits thereof that protect insect microbial agents against ultraviolet irradiation. The invention further relates to methods of treating plants that has been damaged by an insect and/or protecting plants against insect damage. | 2010-08-26 |
20100215631 | ANTI-INFLAMMATORY COMPOSITION COMPRISING GLYCINE AND LACTOFERRIN AND THE USE THEREOF - The present invention relates to nutritional or pharmaceutical compositions comprising lactoferrin and glycine with an anti-inflammatory activity suitable for patients with an inflammatory disease. | 2010-08-26 |
20100215632 | BIOMARKERS OF SIRTUIN ACTIVITY AND METHODS OF USE THEREOF - Provided are methods for monitoring sirtuin modulation in a subject, for example, during therapeutic treatment with a sirtuin modulating compound. The methods involve determining the expression level of one or more sirtuin biomarkers in a biological sample from the subject. Also provided are methods for identifying compounds that modulate the activity of a sirtuin protein using one or more sirtuin biomarkers. | 2010-08-26 |
20100215633 | Method for feeding dairy cows and dairy goats supplements to increase the C2 hxroylated estrogen (C2) to C16 hydroxlated estrogen (C16) ratio secreted in their urine - A feed supplement for dairy cows and goats containing various combinations of whole soy, muscadine grapes, Kudzu leaves, | 2010-08-26 |
20100215634 | VISFATIN THERAPEUTIC AGENTS FOR THE TREATMENT OF ACNE AND OTHER CONDITIONS - The present disclosure relates to compositions and methods for treating acne and other conditions. In particular, the compositions and methods are useful for the treatment of sebum associated conditions. | 2010-08-26 |
20100215635 | SMALL MOLECULES TO INDUCE WEIGHT LOSS OR TO REDUCE WEIGHT GAIN - Embodiments of the present invention include the use of heterocyclic trialkyl ammonium-containing compounds alone or in combination with alkaline phosphatase or other weight loss-inducing drugs or methods to reduce or reverse excess weight gain and obesity as well as reduce the risk of development and help treatment of diseases and unhealthy conditions related to overweight and obesity. | 2010-08-26 |
20100215636 | PEPTIDES DERIVED FROM PLASMINOGEN ACTIVATOR INHIBITOR-1 AND USES THEREOF - The present invention relates to isolated 18-mer peptides corresponding to amino acid residues 369-386 of human plasminogen activator inhibitor 1 (PAI-1) and fragments thereof, compositions that include such peptides, and uses of such compositions for treating thromboembolic diseases and pathological conditions associated with neurological damage. | 2010-08-26 |
20100215637 | Agent for the Treatment of Hormone-Dependent Disorders and Uses Thereof - The present invention relates to novel agents that are useful for treating hormone-dependent disorders. In particular, the present invention relates to A method of modulating a nuclear receptor in vivo comprising the step of administering to a subject in need thereof A nuclear receptor modulating agent comprising a compound or composition capable of altering the endogenous levels of HLS-5 or its activity. | 2010-08-26 |
20100215638 | METHOD FOR TREATMENT OF PROSTATE CANCER AND SCREENING OF PATIENTS BENEFITING FROM SAID METHOD - The invention relates to a method for treating ERG-positive prostate cancer patients with an agent counteracting one or more ERG-associated genes and/or manipulating of one or more ERG-related pathways, optionally in combination with an androgen deprivation therapy. Furthermore, the invention concerns methods for screening prostate cancer patients which may benefit from said treatment, assessing the efficacy of a therapy for treating prostate cancer in a patient, assessing progression of prostate cancer in a patient, selecting an agent to be tested for usefulness in the treatment of prostate cancer, and for assessing prostate carcinogenic potential of an agent. | 2010-08-26 |
20100215639 | Chlamydia Pneumoniae Associated Chronic Intraocular Disorders and Treatment Thereof - Infection by | 2010-08-26 |
20100215640 | METHOD FOR INHIBITING CELLULAR ACTIVATION BY INSULIN-LIKE GROWTH FACTOR-1 - A method of inhibiting cellular activation by Insulin-like Growth Factor-1 (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis, diabetic retinopathy or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit cellular activation by IGF-1. Compounds and compositions for carrying out such methods are also described. | 2010-08-26 |
20100215641 | SCREENING METHOD FOR COMPOUNDS THAT REDUCE ER STRESS - The present invention relates to a cell comprising an Endoplasmic Reticulum (ER) stress element operably linked to a reporter element and an exogenous gene encoding a protein that induces ER stress. Methods of screening using the modified cell, constructs used in the modified cell, the candidate agents identified by the screen and uses thereof are also part of the invention. | 2010-08-26 |
20100215642 | SYNTHETIC RNA-BASED AGONISTS OF TLR7 - The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that selectively induce immune modulatory activity through TLR7. | 2010-08-26 |
20100215643 | ANTI-INFECTIVE FUNCTIONALIZED SURFACES AND METHODS OF MAKING SAME - Devices are provided which are functionalized to include surface regions having anti-infective agents. Methods are provided for functionalizing various material surfaces to include active surface regions for binding anti-infective agents. Methods are provided by which anti-infective moieties or agents are bonded to functionalized surfaces. | 2010-08-26 |
20100215644 | ANALYSIS OF NODES IN CELLULAR PATHWAYS - An embodiment of the present invention is a method for measuring activity of cell pathways, such as the cell cycle pathway and correlating the resulting profile to phenotypes. The resulting correlations are useful in diagnosis, prognosis, selection and development of drug treatment regimens, and drug screening applications. | 2010-08-26 |
20100215645 | GENETIC POLYMORPHISMS ASSOCIATED WITH RHEUMATOID ARTHRITIS, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with rheumatoid arthritis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 2010-08-26 |
20100215646 | IMMUNOSTIMULATORY ACTIVITY OF PALINDROMIC IMMUNE MODULATORY OLIGONUCLEOTIDES (IMO) CONTAINING DIFFERENT LENGTHS OF PALINDROMIC SEGMENTS - The invention provides a palindromic immune modulatory nucleic acid. The invention also provides methods for generating, enhancing and modifying the immune response caused by palindromic immune modulatory compounds used for immunotherapy applications | 2010-08-26 |
20100215647 | Immunological Compositions as Cancer Biomarkers and/or Therapeutics - The present invention concerns antibodies that react immunologically with anti-tumor antigen antibodies and compositions and methods related thereto. In particular, the antibodies that react immunologically with the anti-tumor antigen antibodies are employed in therapeutic, diagnostic, and prognostic embodiments related to cancer, including breast cancer, for example. | 2010-08-26 |
20100215648 | Detecting Agent and Therapeutic Agent for Highly Malignant Breast Cancer - The detection agent for high malignancy breast cancer of the present invention includes an antibody against collagen XIV, or a variant or derivative or fragment of the antibody. The therapeutic agent for high malignancy breast cancer of the present invention includes a conjugate of an anticancer drug and an antibody against that protein, or a variant or derivative or fragment thereof. According to the present invention, it is possible to easily and accurately detect and diagnose high malignancy breast cancer. | 2010-08-26 |
20100215649 | ANTIBODIES FOR NOROVIRUS - Norovirus antigen peptides are described having an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-16, or fragments thereof. Such peptides can be used in the preparation of antiviral therapies such as vaccines, methods of preparing antibodies to the antigen peptides, methods of using the peptides or the corresponding antibodies for detection of norovirus, and compositions of the peptides, DNA and/or antibodies. A kit for the detection of norovirus is also provided. | 2010-08-26 |
20100215650 | METHODS OF TREATING DEMENTIA USING A GM-CSF ANTAGONIST - The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of a patient that has Alzheimer's disease or vascular dementia, or is at risk for developing Alzheimer's disease. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody and pharmaceutical compositions comprising such antagonists. | 2010-08-26 |
20100215651 | Humanized antibodies that bind to CD19 and their uses - The present invention relates to humanized antibodies or fragments thereof that bind to human CD19. More specifically, the present invention relates to a humanized antibody or fragment thereof that binds to human CD19 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 27, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 29; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 31 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 32. | 2010-08-26 |
20100215652 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS - Compounds of formula (I): | 2010-08-26 |
20100215653 | METHODS OF TREATING NEOPLASTIC, AUTOIMMUNE AND INFLAMMATORY DISEASES - Methods of treating cancer and autoimmune and inflammatory diseases are provided. | 2010-08-26 |
20100215654 | Methods of treating Osteoarthritis with IL-6 Antagonists - The present invention provides for methods of treating osteoarthritis with IL-6 antagonists such as IL-6 antibodies. | 2010-08-26 |
20100215655 | ANGIOGENESIS-INHIBITING CHIMERIC PROTEINS AND THE USE - The present invention is directed to DNA sequence encoding angionenesis-inhibiting recombinant chimeric protein, the chimeric protein per se, the pharmaceutical use of the chimeric protein, and to the pharmaceutical composition containing the recombinant protein and the formulation thereof. | 2010-08-26 |
20100215656 | DELETIONS IN DOMAIN II OF PSEUDOMONAS EXOTOXIN A THAT REMOVE IMMUNOGENIC EPITOPES - The invention provides mutated, cytotoxic forms of | 2010-08-26 |
20100215657 | Methods and Compositions Using Klotho-FGF Fusion Polypeptides - The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment. | 2010-08-26 |
20100215658 | VACCINIA VIRUS H3L AND B5R SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF MAKING AND USING SAME - The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to pox virus H3L envelope protein, and combinations thereof. | 2010-08-26 |
20100215659 | FUNCTIONALIZED SURGICAL ADHESIVES - A bioadherent composition includes a first mixture containing a plurality of reactive members of a specific binding pair, said reactive members being bound to a ligand capable of binding a receptor on biological tissue, and a second mixture containing a plurality of complementary reactive members of the specific binding pair, said complementary reactive members being bound to a ligand capable of binding a receptor on biological tissue, said reactive members capable of forming covalent bonds with said complementary reactive members via a reaction selected from Huisgen cycloaddition reactions, Diels-Alder reactions, and/or thiol-alkene reactions. A method for bonding biological tissue involves utilizing the bioadherent composition. | 2010-08-26 |
20100215660 | KRUPPEL-LIKE FACTORS AND FAT REGULATION - Disclosed herein are methods and cell lines used in fat regulation. The methods and cell lines incorporate Krüppel-like factors including, without limitation, klf-1 and klf-3. | 2010-08-26 |
20100215661 | NICOTINAMIDE DERIVATES USEFUL AS P38 INHIBITORS - Compounds of formula (I): | 2010-08-26 |
20100215662 | Anti-influenza M2e antibody - Humanized recombinant and monoclonal antibodies specific for the ectodomain of the influenza virus M2 ion channel protein are disclosed. The antibodies of the invention have anti-viral activity and may be useful as anti-viral therapeutics and/or prophylactic/vaccine agents for inhibiting influenza virus replication and for treating individuals infected with influenza. | 2010-08-26 |
20100215663 | METHODS AND COMPOSITIONS FOR REGULATION OF NEUROLOGICAL CONDITIONS - The invention relates to methods and compositions for regulation of neurological conditions. In particular, methods and compositions for the modulation of the chemokine receptor 1 (CX3CR1) and its ligands are described. | 2010-08-26 |
20100215664 | AMINO ACID SEQUENCES DIRECTED AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH IL-6 -MEDIATED SIGNALLING - The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor. | 2010-08-26 |
20100215665 | MIXED LINEAGE KINASES AND METABOLIC DISORDERS - Methods of treating metabolic stress disorders are disclosed that include administering to a subject a therapeutically effective amount of a composition that specifically inhibits the expression or activity of a mixed lineage kinase (MLK). Also disclosed are methods of identifying candidate compounds for treatment of metabolic stress disorders and methods of diagnosing metabolic stress disorders. | 2010-08-26 |
20100215666 | IL-17 ANTAGONISTIC ANTIBODIES - An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis. | 2010-08-26 |
20100215667 | METHODS AND COMPOSITIONS OF TREATMENT FOR MODULATING THE IMMUNE SYSTEM OF ANIMALS - Methods and compositions are disclosed for the dietary modulation of the immune system and gut microbial response in animals. Applicant has identified that oral administration of a supplemental spray dried plasma purified from animal serum can modulate serum IgG levels for treatment in such things as diminished immune capacity, intestinal microbial balance, autoimmune disorders, potentiation of vaccination protocols, and improvement of overall health and weight gain in animals, including humans. | 2010-08-26 |
20100215668 | METHODS FOR THE TREATMENT OR PREVENTION OF HEMORRHAGIC CONDITIONS - The present invention relates to a method for treatment or prevention of a hemorrhagic condition in a patient by administering plasminogen activator inhibitor-1 (“PAI-1”) and/or an inhibitor of deubiquitinating enzyme CYLD (“CYLD”) to a patient. Pharmaceutical compositions that include one or both of PAI-1 and an inhibitor of CYLD are also disclosed. | 2010-08-26 |
20100215669 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 2010-08-26 |
20100215670 | Immunotoxin Fusions Comprising An Antibody Fragment and a Plant Toxin Linked by Protease Cleavable Linkers - Novel conjugates are disclosed which comprise (a) a ligand that binds to a surface molecule on a target cell, such as a cancer cell; (b) an effector molecule that is to be delivered into the cell, such as a toxin; and (c) a linker sequence that couples the ligand and the effector molecule wherein the linker comprises at least one protease cleavage site corresponding to a protease found in the intracellular trafficking pathway of the effector molecule; wherein the cleavage of the linker by the protease uncouples the effector molecule from the ligand. | 2010-08-26 |
20100215671 | Combination Therapy With Antibody-Drug Conjugates - Methods for the treatment of Hodgkin's lymphoma comprising administering both a chemotherapeutic regimen and an antibody-drug conjugate compound to a subject in need thereof are provided. | 2010-08-26 |
20100215672 | Preparation process and utilization of Poncirus compositions having anti-allergic and antianaphylactic properties - A composition which comprises extracts of a plant of the genus Poncirus. The composition effectively treats allergic conditions, atopic conditions, anaphylactic conditions, and autoimmune conditions. | 2010-08-26 |
20100215673 | Method for treating inflammation and controlled-release material capable of providing same - The present invention relates to methods for treating inflammation associated with bone, joint or connective tissue and an implantable controlled-release material capable of providing these anti-inflammatory activities. In particular, the present invention relates to a method for reducing inflammation in a subject's tissue comprising the step of implanting a material comprising allogenic bone gel into or adjacent to said tissue, wherein said allogenic bone gel reduces the inflammation. | 2010-08-26 |
20100215674 | ENHANCING THE T-CELLS STIMULATORY CAPACITY OF HUMAN ANTIGEN PRESENTING CELLS AND THEIR USE IN VACCINATION - With the current invention, we provide new methods of enhancing the T-cell stimulatory capacity of human dendritic cells (DCs) and their use in cancer vaccination. The method comprises the introduction of different molecular adjuvants to human DCs through transfection with at least two mRNA or DNA molecules encoding markers selected from the group of: CD40L, CD70, constitutively active TLR4 (caTLR4), IL-12p70, EL-selectin, CCR7 and/or 4-1 BBL; or in combination with inhibition of SOCS, A20, PD-L1 and/or STAT3 expression, for example through siRNA transfection. We could show a clear increase in the immunostimulatory capacity of DCs obtained in this way, enabling them to elicit an unexpectedly high T-cell immune response in vitro. Introduction of at least two of the above molecules, in combination with a tumor-specific antigen enables the DCs to elicit a significant host-mediated T-cell immune response in vivo against the tumor antigen and thus makes them very attractive in the manufacturing of anti-cancer vaccines. | 2010-08-26 |
20100215675 | REPLIKIN-BASED COMPOUNDS FOR PREVENTION AND TREATMENT OF INFLUENZA AND METHODS OF DIFFERENTIATING INFECTIVITY AND LETHALITY IN INFLUENZA - The present invention provides methods of differentiating the infectivity and lethality of isolates of influenza virus and provides compounds for diagnosing, preventing, and treating outbreaks of influenza virus including compounds for diagnosing, preventing, and treating across different strains of influenza virus. | 2010-08-26 |
20100215676 | KDR PEPTIDES AND VACCINES COMPRISING THE SAME - The present invention provides nonapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:2, 3, 5, 8, 11, or 12; nonapeptides or decapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:29, 30, 33, 34, 40, or 46; and peptides with cytotoxic T cell inducibility, in which one, two, or several amino acids are substituted or added to the above-mentioned amino acid sequences, as well as pharmaceuticals for treating or preventing tumors, where the pharmaceuticals comprise these peptides. The peptides of this invention can be used as vaccines. | 2010-08-26 |
20100215677 | PDZ DOMAIN INTERACTIONS AND LIPID RAFTS - Methods for modulating immune cell signaling are provided. In general such methods involve modulating an interaction between a PDZ protein and a PDZ ligand protein whose interaction affects the composition and/or distribution of lipid rafts in an immune cell. Modulators that enhance or inhibit such interactions are also disclosed, as well as methods of screening for such modulators. | 2010-08-26 |
20100215678 | Ras Mutation and Compositions and Methods Related Thereto - Disclosed are newly discovered Ras mutations and combinations of mutations, proteins and peptides and fusion proteins containing these mutations, nucleic acid molecules encoding such proteins, peptides, and fusion proteins, and a variety of tools and diagnostic, therapeutic, and screening methods associated with the use of such mutations. | 2010-08-26 |
20100215679 | METHODS AND COMPOSITIONS FOR TREATING TULAREMIA - The disclosure provides an antigenic composition useful for immunization against tularemia. The disclosure provides a method for producing a vaccine for preventing tularemia in humans and animals, a new vaccine against tularemia in humans and animals, and a new approach to producing vaccines against tularemia. | 2010-08-26 |
20100215680 | REPLIKIN PEPTIDES AND ANTIBODIES THEREFOR - The present invention provides a new class of peptides related to rapid replication and their use in diagnosing, preventing and treating disease. | 2010-08-26 |
20100215681 | FUSION PROTEINS COMPRISING HIV-1 TAT AND/OR NEF PROTEINS - The invention provides (a) an HIV Tat protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Nef protein or derivative thereof; or (b) an HIV Nef protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Tat protein or derivative thereof; or (c) an HIV Nef protein or derivative thereof linked to an HIV Tat protein or derivative thereof and a fusion partner. The invention further provides for a nucleic acid encoding such a protein and a host cell, such as | 2010-08-26 |
20100215682 | DELETION OF THE BETA 20-21 LOOP IN HIV GP120 EXPOSES THE CD4 BINDING SITE FOR IMPROVED ANTIBODY BINDING AND ANTIBODY INDUCTION - Disclosed herein are isolated immunogens including variant gp120 polypeptides. In an example, a variant gp120 polypeptide includes a deletion of at least 8 consecutive residues of the fourth conserved loop (C4) between residues 419 and 434 of gp120 according to HXB2 numbering. Also provided are isolated nucleic acid molecules encoding the disclosed isolated immunogens. In an example, an isolated nucleic acid molecule further includes a nucleic acid molecule encoding a hepatitis B surface antigen or a variant thereof. Compositions including the isolated immunogens including variant gp120 polypeptides are also disclosed. In some examples, a composition further includes a carrier protein, such as a hepatitis B surface antigen or a variant thereof (natural or recombinant). Viral-like particles are also provided including any of the disclosed isolated immunogens or compositions. Also disclosed are uses of these variant gp120 polypeptides and nucleic acids encoding variant polypeptides, such as to induce an immune response to HIV-1. | 2010-08-26 |
20100215683 | PROTECTIVE ANTIGENS FOR GROUP B STREPTOCOCCUS HYPERVIRULENT STRAINS - The invention provides protective antigens for Group B streptococcus hypervirulent strains. The fragments are useful in vaccine compositions to induce protection against | 2010-08-26 |
20100215684 | STREPTOCOCCUS M PROTEIN, IMMUNOGENIC FRAGMENTS, NUCLEIC ACIDS AND METHODS OF USE - Isolated M proteins, or M-like proteins, of | 2010-08-26 |
20100215685 | ACYL PSEUDODIPEPTIDES WHICH CARRY A FUNCTIONALIZED AUXILIARY ARM - The present invention is directed in particular to dipeptide-like compounds derived from functionally substituted amino acids, having fatty acid chains bound thereto through amidification of the amine functional groups of said dipeptide-like compounds, one end portion of which bears an accessory functional side chain spacer, with the other end portion being an acid group either in neutral or charged state. | 2010-08-26 |
20100215686 | Process for Manufacturing Vaccines - The present application discloses an improved method for conducting saccharide-protein conjugation reactions using carbodiimide condensation chemistry. Depending the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed. | 2010-08-26 |
20100215687 | Soluble Fiber Combinations for Weight Control and Improving Parameters of Cardiovascular Health - A food or pharmaceutical agent is provided for treating or offsetting the risks of a disease or disorder such as a cardiovascular disease, a hypercholesterolemia disorder, a low serum high density lipid (HDL)/low density lipid (LDL) ratio, a hypertriglyceridemia disorder, and diabetes includes a pharmaceutical carrier, and a composition including a purified glucomannan and at least one galactomannan. A method for treating or offsetting the risks of such a disease or disorder includes the step of administering to a human in need thereof an effective amount of the pharmaceutical composition to treat the cardiovascular disease. | 2010-08-26 |
20100215688 | COMPOSITIONS FOR SUPPRESSING OBESITY - Disclosed herein is a composition for suppressing and preventing obesity and related adult diseases, comprising Herba Ephedrae and Thallus Laminariae seu Eckloniae, or comprising Herba Ephedrae, Thallus Laminariae seu Eckloniae and Radix et Rhizoma Rhei. | 2010-08-26 |
20100215689 | Soluble Fiber Combinations for Weight Control and Improving Parameters of Cardiovascular Health - A food or pharmaceutical agent is provided for treating or offsetting the risks of a disease or disorder such as a cardiovascular disease, a hypercholesterolemia disorder, a low serum high density lipid (HDL)/low density lipid (LDL) ratio, a hypertriglyceridemia disorder, and diabetes includes a pharmaceutical carrier, and a composition including a purified glucomannan and at least one galactomannan. A method for treating or offsetting the risks of such a disease or disorder includes the step of administering to a human in need thereof an effective amount of the pharmaceutical composition to treat the cardiovascular disease. | 2010-08-26 |
20100215690 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 2010-08-26 |
20100215691 | RECOMBINANT VIRAL VECTORS - The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention. | 2010-08-26 |
20100215692 | Dengue Chimeric Viruses - The invention relates to Dengue chimeric viruses which are less prone to accumulate point mutations and genetic variations. In these Dengue chimeric viruses, the NS5 gene, which encodes polymerase, has been replaced by the corresponding NS5 sequence of a Yellow Fever virus. | 2010-08-26 |
20100215693 | IMMUNOLOGICAL HERPES SIMPLEX VIRUS ANTIGENS AND METHODS FOR USE THEREOF - The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 2010-08-26 |
20100215694 | Infectious cDNA of North American Porcine Reproductive and Respiratory Syndrome (PRRS) Virus and Uses Thereof - The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of North American PRRS virus. The invention also provides vaccines comprising genetically modified North American PRRS virus, RNA molecules, plasmids and viral vectors comprising the isolated polynucleotide molecules. Also provided are isolated polynucleotide molecules further comprising at least one nucleotide sequence that encodes a detectable heterologous antigenic epitope, and vaccines comprising North American PRRS virus, RNA molecules, plasmids and viral vectors comprising such isolated polynucleotide molecules. | 2010-08-26 |
20100215695 | HIV PREVENTIVE VACCINE BASED ON HIV SPECIFIC ANTIBODIES - The present invention relates to a method for producing a HIV vaccine, preventing infection with HIV and/or preventing the development of HIV infection in an individual. In particular, the present invention provides formation of HIV specific antibodies capable to recognize and bind to substantially all HIV-isoforms as an immune response in an individual, which bind to existing in a current epidemiologic cohort HIV-subtypes and mutants selected after antiretroviral therapy. The present invention also relates to HIV-1 peptides/polypeptides/proteins selection with reverse panning technique, LC mass spectrometry identification of HIV-1 env peptides/polypeptides/proteins, gp120 and its fragment in particular, production of recombinant HIV-1 env peptides in suitable host with necessary glycosylation— | 2010-08-26 |
20100215696 | EFFICIENTLY REPLICABLE HEPTITIS C VIRUS MUTANT, A HEPTITIS C VIRUS MUTANT COMPRISING REPORTER GENE, A METHOD OF PREPARING OF HCV VACCINE USING THE SAME AND A METHOD OF SCREENING ANTI HCV COMPOSITION USING THE SAME - The present invention relates an efficiently replicating a modified hepatitis virus (HCV) mutant, and a modified HCV further comprising reporter gene, a method of preparing HCV vaccine using the same, and a method of screening anti-HCV material using the same. The present invention is to overcome the defect that the conventional HCV cell culture systems are unable to produce a sufficient amount of virus, thereby causing it difficult to efficiently induce or measure HCV infection. Because the present invention can allow production of HCV in a large amount an efficiently observing HCV infection in a living cell, it can make it possible to achieve many studies that were previously highly challenging, including studies on infection routes, and assembly and release of HCV. In addition, the present invention contributes to studies for searching anti-HCV agents being inhibiting all stages of the HCV life cycle, not being limited to HCV replication. | 2010-08-26 |
20100215697 | METHODS AND MATERIALS FOR MAKING AND USING VACCINES - This document relates to methods and materials for making and using vaccines. For example, vaccine preparations (e.g., whole cell vaccines and cell lysate vaccines) that can be used to treat cancer (e.g., human ovarian cancer) are provided. | 2010-08-26 |
20100215698 | METHOD OF TREATING CANCER CELLS TO CREATE A MODIFIED CANCER CELL THAT PROVOKES AN IMMUNOGENIC RESPONSE - The present invention relates to a delipidation method employing a solvent system useful for extracting lipids from cancer cells, thereby creating a modified cancer cell particle. Upon delipidation of the cancer cells, a portion of the cancer cell antigens remain intact. These exposed antigens, or epitopes, foster and promote antibody production. The resulting modified cancer cell particle, or portions of the cancer cell, initiate a positive immunogenic response when administered to an animal or human and help to treat, prevent or delay the onset of cancer. The present invention provides autologous and heterologous vaccine compositions comprising the modified cancer cell with a pharmaceutically acceptable carrier. The present invention provides method of administering these vaccines to treat, prevent or delay the onset of cancer. | 2010-08-26 |
20100215699 | LACTOFERRIN AS A RADIOPROTECTIVE AGENT - This present invention relates to the field of protecting against, or rectifying the effects of damaging ionizing irradiation. The method of treatment involves oral administration of a lactoferrin composition, alone or in combination with other treatments, both in combination with other radio-protective agents and/or the standard of care. Further, the method of treatment provides for a topical administration of lactoferrin to treat lesions caused by local damaging irradiation. | 2010-08-26 |
20100215700 | Shear Gels and Compositions Comprising Shear Gels - The present invention is directed to shear gels and topical compositions comprising the same. The topical compositions can be substantially free of silicone elastomers and yield excellent sensory characteristics when applied. | 2010-08-26 |
20100215701 | COSMETIC COMPOSITION COMPRISING A FINE POWDER - The present invention relates to cosmetic compositions used in the care and make-up field. This composition mainly comprising a continuous aqueous phase, a fatty phase and a fine and porous pulverulent copolyamide powder phase, is in the form of creamy, liquid or gelled compositions. This is in particular an emulsion, but it may also be a two-phase formulation or composition in which the fatty phase and aqueous phase are separate. The invention more particularly relates to cosmetic care and/or make-up compositions having a continuous aqueous phase in the case of an oil-in-water emulsion. | 2010-08-26 |
20100215702 | MICROPARTICLES COMPRISING PCL AND USES THEREOF - The invention relates to a process for preparing PCL-comprising microparticles, to microparticles obtainable by said process, to gel hence obtained and to several uses of the gel such as for the preparation of a medicament for treating a skin abnormality or disfigurement, and/or for controlling bladder function and/or controlling gastric reflux and/or for treating erectile dysfunction and/or for treating vocal cords. The gel may also be used for cosmetic applications. | 2010-08-26 |
20100215703 | Composition Containing Vesicle-Silica Complex, And Process For Production Thereof - To provide a vesicle-containing composition wherein the stability is improved and the rate of releasing drug or perfume is sufficiently restricted during administration in vivo or application to the skin surface. Silica polymerization on the outer surfaces of vesicles is facilitated by adding a specifically structured water-soluble silane derivative to an aqueous composition containing the vesicles composed of a surfactant and mixing them together, and vesicle-silica composites having silica-coated outer surfaces can be obtained, resulting in the improved stability of the vesicle-containing composition as well as the improved effect of restricting the rate of releasing drug or perfume during administration in vivo or application to the skin surface. | 2010-08-26 |
20100215704 | METHODS AND PRODUCTS FOR IMPROVING WOUND HEALING - Morpholino compounds of Formula (I) | 2010-08-26 |
20100215705 | Use of Colloidal Clays for Sustained Release of Active Ingredients - One aspect of the invention is a method of controlling target living species with an active ingredient over an extended period of time. This method sorbs an active ingredient into colloidal clay. Next, a polymer pellet recalcitrant to release of the active ingredient is loaded with the sorbed colloidal clay. Finally, the loaded polymer pellet is formed into a barrier, which is adapted to be placed at a location for controlling a target living species. Another aspect is a barrier for controlling a target living species. The formed barrier contains polymer pellets loaded with colloidal clay sorbed with an active ingredient that controls the target living species. The sorbed clay loaded polymer pellets are recalcitrant to release of the active ingredient. | 2010-08-26 |
20100215706 | SPINOSYN FUMIGANTS - Methods of controlling arthropod pests by dispersing spinosyn compositions in the form of aerosols, fogs, smokes, or vapors are disclosed. | 2010-08-26 |
20100215707 | ACTIVATED CREATININE AND PRECURSORS THEREOF AS ANTIBACTERIAL AGENTS, COMPOSITIONS AND PRODUCTS CONTAINING SUCH AGENTS AND USES THEREOF - Creatinine, creatinine precursors or the pharmaceutically acceptable salts thereof are activated to function as an antibacterial agent which has broad spectrum activity and is beneficially used in a variety of applications, such as antimicrobial wound dressings, compositions for topical delivery of the antibacterial agent and for preventing and/or inhibiting the occurrence or spread of bacterial infection, as well as the growth of odor-causing bacteria, to name a few. | 2010-08-26 |
20100215708 | COATING OF DEVICES WITH EFFECTOR COMPOUNDS - This invention is directed to substrates, materials and devices coated with a gel, foam, film, particle or composition comprising a polymei solvent and effector compounds attached thereto, processes of producing the same, and methods of use thereof, of in, inter-alia, biological applications, including preventing infection and the treatment of various diseases. | 2010-08-26 |
20100215709 | MEDICAL DEVICE WITH INFLAMMATORY RESPONSE-REDUCING COATING - Implantable non-bioabsorbable medical devices have an amphiphilic coating for reducing the inflammatory response to the device after implantation. | 2010-08-26 |
20100215710 | Beta-2 Adrenergic Receptor Agonists and Antagonists and Modulation of Wound Healing - Methods for increasing rate of healing of wounds in epithelial tissues by administration of beta-2 adrenergic receptor antagonists to target patients are provided. Methods for decreasing cell growth around implanted devices and methods for decreasing wound contraction by administration of beta-2 adrenergic receptor agonists are also provided. Pharmaceutical compositions and kits including beta-2 adrenergic receptor agonists and antagonists are described, as are devices coated with beta-2 adrenergic receptor agonists. | 2010-08-26 |
20100215711 | STABILIZED ENZYME COMPOSITIONS - A medical device includes a base material having an immobilized fibrinolytic enzyme and dextran sulfate. The dextran sulfate has a molecular weight that is less than 40 kilo dalton (kDa). The medical device is formed from at least a base material. A fibrinolytic enzyme is immobilized on the base material. The fibrinolytic enzyme is stabilized with a dextran sulfate having a molecular weight of less than 40 (kDa). | 2010-08-26 |